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Terminal deoxynucleotidyl transferase is an enzyme which has the unique 
property of polymerizing polydeoxynucleotides onto a primer in the absence of a 
template (1, 2). This enzyme is found both in the thymus and the bone marrow of 
birds, rodents, and humans (3-7). Whether the marrow cells that contain 
terminal transferase are related to thymocytes, or are on a separate pathway of 
differentiation, is not yet known (7, 8). 
To determine the lineage of the murine bone marrow cells that have terminal 
transferase, we have investigated whether these cells have the antigen Thy-1 
which is characteristic of T cells and thymocytes, or whether Thy-1 can be 
induced on the cells by treatment with thymopoietin (9). Thymopoietin s known 
to induce a set of characteristic T-cell markers including the Thy-1 alloantigen 
on the surface of a subpopulation of bone marrow cells committed to T-cell 
differentiation (prothymocytes) (10). Destruction of Thy-l-positive cells after 
exposure to thymopoietin allows elimination of a substantial fraction of those 
bone marrow cells that can repopulate an irradiated thymus (11). We find that 
such an elimination after induction with the thymic polypeptide removes a 
substantial mount of terminal transferase from the bone marrow cell popula- 
tion, suggesting that at least one-half of the marrow cells bearing this enzyme 
are related to those found in the thymus. 
Mater ia ls  and Methods 
Mice. C57BL6/J and A/J mice from The Jackson Laboratory, Bar Harbor, Maine, were used. 
Cell Preparation. Thymocytes and marrow lymphocytes extracted from femoral and tibial 
plugs were suspended in phosphate-buffered saline (PBS)-5% fetal calf serum (FCS) (Micro- 
biological Associates, Bethesda, Md.) as described (7). 
Induction of Cytotoxic Antibodies. Bovine thymopoietin was prepared as described (9). It was 
dissolved in PBS-2% FCS at a final concentration of500 ng/ml. In a typical experiment cells were 
incubated at 4 × 107/ml for 2.5 h at 37°C, then washed twice with PBS-2% FCS. 
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Complement-Mediated Cytotoxicity. Anti-Thy-l.2 was either a gift of Dr. E. A. Boyse (Memo- 
rial Sloan-Kettering Cancer Center, New York) or was prepared as described (12). The method of 
treatment of lymphoid cells with anti-Thy-l.2 serum and complement (C) has been described 
previously (12). In a representative experiment, l0s cells/ml were incubated with Thy-l.2 antise- 
rum at a dilution of 1:50 at room temperature for30 min, washed once, and incubated for a further 
1/2 h with rabbit C (1:10 dilution) at 37°C. The cells were then pelleted and washed several times. 
In cases where viability was leas than 85%, Ficol-Hypaque centrifugation was used to remove dead 
cells (13), before the cells were pelleted and frozen at -70°C. 
Extraction of Terminal Transferase. The procedure has been previously described (7), except 
that in order to inhibit protease activity the inhibitor phenylmethylsulfonylfluoride (PMSF) 
(Sigma Chemical Co., St. Louis, Mo.) was introduced at the time of the first thawing of the sample 
at a concentration f 4 gmol/108 cells in 4.3 mmol of ethanol (per 5-ml vol). 
PhosphoceUulose Chromatography. The procedure was modified (5, 7) to examine the smaller 
amounts of activity present in the bone marrow. A 4 cm column, rather than 12 cm was used, the 
gradient was only 25 ml in total vol, and fractions of 0.25-0.32 ml size were collected. Terminal 
transferase assays were done as previously described (5, 7). 
Resu l ts  
To determine the effect of anti -Thy- l .2 and C upon terminal  t ransferase 
activity in thymocytes,  the amount  of terminal  t ransferase in the cells remain-  
ing after t reatment  was measured and expressed as specific activity of enzyme 
per 109 remain ing viable cells. Although ant i -Thy- l .2 serum and C ki l led most 
thymocytes (94% were specifically kil led by ant iserum in exp. 1, Table I), the 
remain ing cells had the same activity per cell of terminal  t ransferase as cells 
treated with normal  mouse serum (Table I, l ines 1 and 2). This level of enzyme 
activity is s imi lar to that  in untreated thymocytes (reference 7 and unpubl ished 
data). The few ant i -Thy- l .2-resistant cells are therefore not different from the 
average normal  thymocyte population. 
The effect of anti -Thy- l .2 t reatment  on the terminal  transferase content of the 
marrow lymphocytes was studied using the same protocol used for the thymo- 
cytes. In the marrow most cells lack detectable terminal  t ransferase (P. C. 
Kung,  unpubl ished results) and therefore if the 2-5% Thy-l -posit ive cells in 
bone marrow (10, 11) were responsible for all of the marrow terminal  transfer- 
ase, ant i -Thy- l .2 serum should great ly reduce the specific activity of the enzyme 
in marrow cells. On the contrary, terminal  t ransferase activity was unchanged 
by t reatment  of marrow cells with ant i -Thy- l .2 and C (Table I, l ines 1, 2, 4, 7, 
and 8). The majority of the enzyme-posit ive c lls of the marrow therefore lack 
Thy-1 determinants  on their  surface. 
To determine if Thy-1 determinants  could be induced onto the surface of the 
terminal  transferase-containing cells, marrow cells were treated with thymo- 
poietin for 2-3 h. When the thymopoiet in-treated cells were exposed to anti-Thy- 
1.2 antibody, the terminal  t ransferase specific activity was reduced by over 50% 
(Table I, l ines 3, 6, and 10). Because t reatment  with thymopoiet in alone did not 
alter the terminal  transferase content of the marrow cells (Table I, l ines 5 and 9) 
it appears that  thymopoiet in induced Thy-l .2 expression on the surface of a 
significant portion of the terminal  transferase-containing cells, thus mak ing  
them susceptible to the ant iserum. The number  of cells specifically ki l led in the 
marrow by anti -Thy- l .2 t reatment  was impossible to determine with accuracy 
because there was a high background ki l l ing by C alone. In some cases (exps. 1 
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TABLE I 
Effect of Antibody Treatment on Cell Number and Terminal Transferase Levels in 
C57BL/6J and A/J  Mice 
Inductive treatment Postinduction ant iserum + C 
Termina l  transferase remain ing  
Bone marrow 
Thymocytes lymphseytes 
Exp. 1, C57BL]6J 
Exp. 2, A/J 
Exp. 3, A/J 
U/IO 9 cells 
None Normal mouse serum 2.69 0.208 
None Anti-Thy-l:2 2.50 0.188 
Thymopoietin Anti-Thy- 1.2 - 0.061 
None Anti-Thy- 1.2 - 0.216 
Thymopo ie t in  Normal  mouse  serum - 0.204 
Thymopo ie t in  Anti-Thy-l.2 - O. 107 
None Normal mouse serum - 0.206 
None Anti-Thy- 1.2 - 0.243 
Thymopoietin Normal mouse serum - 0.198 
Thymopoietin Anti-Thy- 1.2 - 0.102 
and 2, Table I) 5-10% specific killing over the C background could be detected, 
but in experiment three (Table I) no specific killing over background was seen. 
We have previously noted that thymocytes contain two forms of terminal 
transferase, one of which elutes from phosphocellulose at lower salt concentra- 
tion than the other (7, 8). We have also found that well-defined two-peak profiles 
of elution from phosphocellulose are found most reproducibly if a protease 
inhibitor, PMSF, is added to the extraction medium (unpublished observations). 
Even using the protease inhibitor, bone marrow terminal transferase did not 
give a two-peak profile of elution (Fig. 1). The majority of the enzyme, however, 
elutes in the region of the column where the low salt, "peak r' form of terminal 
transferase lutes (compare figures in reference 7). Treatment of cells with 
thymopoietin followed by anti-Thy-l.2 serum produced a generalized ecrease of 
terminal transferase throughout he phosphocellulose elution profile (Fig. 1) 
while neither anti-Thy-l.2 treatment alone or thymopoietin alone had any 
reproducible ffect. In the experiment of Fig. 1, a 75% reduction of terminal 
transferase was produced by thymopoietin plus anti-Thy-l.2 treatment; this is 
the largest effect we have seen. 
Table II presents the averaging of the results of five experiments. It is clear 
that although there is no significant loss of marrow terminal transferase after 
anti-Thy-l.2 treatment, or C treatment, of mouse bone marrow cells, the elimi- 
nation of Thy-l.2 cells after induction with thymopoietin results in a significant 
decrease of terminal trausferase. This loss represents an average of 58% with a 
range of loss of enzyme from 50 to 75%. 
Discussion 
In order to investigate the nature of the bone marrow cells containing termi- 
nal transferase, we have taken advantage of the ability to induce a thymus- 
specific antigen, Thy-1, on bone marrow cells using the thymic polypeptide, 
thymopoietin. After this treatment, cells now expressing the antigen can be 
killed by cytotoxic antibody treatment. As our results show, this leads to a 
destruction of marrow cells carrying terminal transferase. Therefore, a signifi- 
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Fza. 1. Elimination of terminal transferase-bearing cells in bone marrow by induction 
and cytotoxic antibodies. C', C-treated samples. Anti-Thy-l.2 treated with antiserum. 
Treatment is described in the Materials and Methods. See text for protocol. 
TABLE II 
Average Results of Induction and Cytotoxic Elimination of Terminal 
Transferase Levels in Marrow Cells 
Terminal transferase 
Inductive treatment Postinductive treatment 
remaining* 
U/ IO ~ cel ls  
None None 0.208 
None Normal mouse serum 0.216 
None Anti-Thy-l.2 + C 0.191 
Thymopoietin Normal mouse serum 0.219 
+ complement 
Thymopoietin Anti-Thy-l.2 + C 0.090 
*Each value represents average of three or four determinations, with standard deviation less than 20%. 
cant portion of the cells in the mouse marrow which bear terminal transferase 
must already be committed to the T-cell pathway. Since thymopoietin appears to 
selectively induce a population already committed to development along the T- 
cell pathway (14), and does not affect lymphocytes destined for the B-cell 
pathway, the population of cells we have eliminated probably represents a 
portion of the prothymocyte population of the marrow. 
In earlier papers (7, 8, 15) it has been suggested that the marrow cells bearing 
terminal transferase are related developmentally to the thymus cells which bear 
high levels of this enzyme. Here, we present data supporting this supposition. 
Whether all the marrow cells bearing terminal transferase are destined to enter 
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the T-cell pathway is uncertain. In our experiments we may not have eliminated 
all the measurable terminal transferase because of the incompleteness of our 
induction or incompleteness of killing by cytotoxic antibody, or both. We are 
unable to settle this question given the current limits in our technique. How- 
ever, we are investigating the possibility that terminal transferase may also be 
present in pre-B cells using an experimental pproach similar to that described 
here. 
We can say from our results that terminal transferase is a valuable marker for 
studying T-cell development. I  is now the earliest known property of cells that 
can undergo thymus-dependent development, and it clearly disappears before 
the final maturation of the T cell to a circulating lymphocyte (15, 16). Studying 
the appearance and disappearance of this enzyme in selected cell populations 
may help explain the development of function by T cells. 
We are very grateful for the technical and theoretical advice and antibody supplied by Doctors E. 
A. Boyse and M. P. Scheid. These experiments would not have been possible without he technical 
assistance of Joan Hugenberger and Laila Boudreau. 
Received for publication 7 May 1976. 
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